Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 5;8(2):e001222. doi: 10.1136/jitc-2020-001222

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Overview on targeting approaches for cancer-associated glycosylation. (A) Tumor-associated carbohydrates (TACA) can serve as tumor-specific antigen and be approached with antibody-dependent cellular cytotoxicity (ADCC)-inducing or complement-dependent cytotoxicity (CDC)-inducing antibodies or with antibodies carrying a payload (chemotherapy or even enzyme). (B) Chimeric antigen receptor (CAR) expressing immune cells could be redirected towards TACA-presenting tumors. Similarly, bispecific antibodies could be used to direct immune cells to TACA-expressing tumors (not shown). (C) TACA such as sialoglycans can engage immune receptors including inhibitory Siglec receptors on T cells and myeloid cells and improve anticancer immunity directly. ADC, antibody-drug conjugates.